Phuong N. Huynh

Array ( [id] => 14975529 [patent_doc_number] => 10441651 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-15 [patent_title] => Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells [patent_app_type] => utility [patent_app_number] => 14/810466 [patent_app_country] => US [patent_app_date] => 2015-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 29642 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 247 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14810466 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10450749 [patent_doc_number] => 20150335762 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-26 [patent_title] => 'TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE IMMUNE RESPONSES TO THERAPEUTIC PROTEINS' [patent_app_type] => utility [patent_app_number] => 14/810427 [patent_app_country] => US [patent_app_date] => 2015-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 36706 [patent_no_of_claims] => 116 [patent_no_of_ind_claims] => 50 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14810427 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10684408 [patent_doc_number] => 20160030554 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-04 [patent_title] => 'TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ALLERGY THERAPY' [patent_app_type] => utility [patent_app_number] => 14/810457 [patent_app_country] => US [patent_app_date] => 2015-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 31539 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14810457 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10435858 [patent_doc_number] => 20150320870 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-12 [patent_title] => 'TOLEROGENIC SYNTHETIC NANOCARRIERS FOR INDUCING REGULATORY B CELLS' [patent_app_type] => utility [patent_app_number] => 14/810476 [patent_app_country] => US [patent_app_date] => 2015-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 32102 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14810476 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10676505 [patent_doc_number] => 20160022650 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-28 [patent_title] => 'TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE CYTOTOXIC T LYMPHOCYTE RESPONSES' [patent_app_type] => utility [patent_app_number] => 14/810450 [patent_app_country] => US [patent_app_date] => 2015-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 36111 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14810450 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14881629 [patent_doc_number] => 10420835 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-09-24 [patent_title] => Tolerogenic synthetic nanocarriers for antigen-specific deletion of T effector cells [patent_app_type] => utility [patent_app_number] => 14/810472 [patent_app_country] => US [patent_app_date] => 2015-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 5 [patent_no_of_words] => 34024 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 266 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14810472 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10443321 [patent_doc_number] => 20150328333 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-19 [patent_title] => 'TOLEROGENIC SYNTHETIC NANOCARRIERS' [patent_app_type] => utility [patent_app_number] => 14/810418 [patent_app_country] => US [patent_app_date] => 2015-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 32216 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14810418 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11757309 [patent_doc_number] => 20170204178 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-20 [patent_title] => 'MOLECULES WITH SPECIFICITY FOR CD79 AND CD22' [patent_app_type] => utility [patent_app_number] => 15/326501 [patent_app_country] => US [patent_app_date] => 2015-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 47380 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15326501 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16755361 [patent_doc_number] => 10973889 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-13 [patent_title] => Method for improving the benefit of organ transplant [patent_app_type] => utility [patent_app_number] => 15/328879 [patent_app_country] => US [patent_app_date] => 2015-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 50 [patent_no_of_words] => 33684 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 166 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15328879 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14852205 [patent_doc_number] => 10414814 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-09-17 [patent_title] => Tumor-selective CTLA-4 antagonists [patent_app_type] => utility [patent_app_number] => 15/322438 [patent_app_country] => US [patent_app_date] => 2015-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 11 [patent_no_of_words] => 29223 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15322438 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10980042 [patent_doc_number] => 20160176986 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-23 [patent_title] => 'HIGH-CONCENTRATION MONOCLONAL ANTIBODY FORMULATIONS' [patent_app_type] => utility [patent_app_number] => 14/752670 [patent_app_country] => US [patent_app_date] => 2015-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 17338 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14752670 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15309087 [patent_doc_number] => 10519234 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-31 [patent_title] => NKp46 binding proteins [patent_app_type] => utility [patent_app_number] => 15/321650 [patent_app_country] => US [patent_app_date] => 2015-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 36 [patent_no_of_words] => 43542 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 291 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15321650 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15245279 [patent_doc_number] => 10508153 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-17 [patent_title] => Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof [patent_app_type] => utility [patent_app_number] => 14/743886 [patent_app_country] => US [patent_app_date] => 2015-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 57 [patent_figures_cnt] => 51 [patent_no_of_words] => 43257 [patent_no_of_claims] => 61 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14743886 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10474848 [patent_doc_number] => 20150359865 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-17 [patent_title] => 'TOLEROGENIC SYNTHETIC NANOCARRIERS FOR T-CELL-MEDIATED AUTOIMMUNE DISEASE' [patent_app_type] => utility [patent_app_number] => 14/742583 [patent_app_country] => US [patent_app_date] => 2015-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 18924 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14742583 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10389813 [patent_doc_number] => 20150274820 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-01 [patent_title] => 'STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF' [patent_app_type] => utility [patent_app_number] => 14/741430 [patent_app_country] => US [patent_app_date] => 2015-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 28931 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14741430 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10459556 [patent_doc_number] => 20150344572 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-03 [patent_title] => 'ANTI-CD160 SPECIFIC ANTIBODIES FOR THE TREATMENT OF EYE DISORDERS BASED ON NEOANGIOGENESIS' [patent_app_type] => utility [patent_app_number] => 14/728253 [patent_app_country] => US [patent_app_date] => 2015-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 9993 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14728253 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10450655 [patent_doc_number] => 20150335669 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-26 [patent_title] => 'CHEMICALLY MODIFIED TARGETING PROTEIN AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 14/717753 [patent_app_country] => US [patent_app_date] => 2015-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 17562 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14717753 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10346235 [patent_doc_number] => 20150231241 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-20 [patent_title] => 'COMBINATION THERAPY FOR INDUCING IMMUNE RESPONSE TO DISEASE' [patent_app_type] => utility [patent_app_number] => 14/703082 [patent_app_country] => US [patent_app_date] => 2015-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 52250 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14703082 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11442010 [patent_doc_number] => 20170043031 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-16 [patent_title] => 'IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER' [patent_app_type] => utility [patent_app_number] => 15/306351 [patent_app_country] => US [patent_app_date] => 2015-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 53689 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15306351 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10399445 [patent_doc_number] => 20150284454 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-08 [patent_title] => 'ANTI-SERUM ALBUMIN BINDING VARIANTS' [patent_app_type] => utility [patent_app_number] => 14/691913 [patent_app_country] => US [patent_app_date] => 2015-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 24652 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14691913 [rel_patent_id] =>[rel_patent_doc_number] =>)